Interaction of TP53 mutations with trastuzumab in HER2-positive patients with operable breast cancer

被引：0

作者：

Kotoula, V. ^{[1
]}

Zagouri, F. ^{[1
]}

Alexopoulou, Z. ^{[2
]}

Gogas, H. ^{[1
]}

Lakis, S. ^{[1
]}

Pentheroudakis, G. ^{[1
]}

Bobos, M. ^{[1
]}

Papadopoulou, K. ^{[1
]}

Tsolaki, E. ^{[1
]}

Skondra, M. ^{[1
]}

Karavasilis, V. ^{[1
]}

Koutras, A. ^{[1
]}

Chrisafi, S. ^{[1
]}

Christodoulou, C. ^{[1
]}

Papakostas, P. ^{[1
]}

Linardou, H. ^{[1
]}

Markopoulos, C. ^{[1
]}

Zografos, G. ^{[1
]}

Samantas, E. ^{[1
]}

Fountzilas, G. ^{[1
]}

机构：

[1] Data Off, Hellen Cooperat Oncol Grp, Athens, Greece

[2] Hlth Data Specialists Ltd, Biostat, Athens, Greece

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30765-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1813

引用

页码：S270 / S270

页数：1

共 50 条

[1] Early onset HER2-positive breast cancer is associated with germline TP53 mutations
Melhem-Bertrandt, Amal
Bojadzieva, Jasmina
Ready, Kaylene J.
Obeid, Elias
Liu, Diane D.
Gutierrez-Barrera, Angelica M.
Litton, Jennifer K.
Olopade, Olufunmilayo I.
Hortobagyi, Gabriel N.
Strong, Louise C.
Arun, Banu K.
CANCER, 2012, 118 (04) : 908 - 913
[2] A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations
Wilson, J. R. F.
Bateman, A. C.
Hanson, H.
An, Q.
Evans, G.
Rahman, N.
Jones, J. L.
Eccles, D. M.
JOURNAL OF MEDICAL GENETICS, 2010, 47 (11) : 771 - 774
[3] Prevalence of Germline TP53 Mutations in Young Women with HER2-Positive Breast Cancer.
Dick, M. G.
Masciari, S.
Miron, A.
Miron, P.
Foley, K.
Gelman, R.
Dillon, D. A.
Richardson, A. L.
Verselis, S. J.
Lypas, G.
Krop, I. E.
Garber, J. E.
CANCER RESEARCH, 2011, 71
[4] TP53 mutations among molecular subtypes of HER2-positive tumors
Helland, Å
Nicolau, M
Ji, Y
Langerod, A
Sommervoll, DE
Bergamaschi, A
Pollack, JR
Borresen-Dale, AL
Jeffrey, SS
BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
[5] TP53 mutations among molecular subtypes of HER2-positive tumors
Å Helland
M Nicolau
Y Ji
A Langerød
DE Sommervoll
A Bergamaschi
JR Pollack
A-L Børresen-Dale
SS Jeffrey
Breast Cancer Research, 7
[6] Increased Rate of HER2-Positive Breast Cancers among Women with Germline TP53 Mutations
Melhem-Bertrandt, A.
Ready, K. J.
Gutierrez-Barrera, A. M.
Litton, J.
Strong, L. C.
Olopade, O. I.
Hortobagyi, G. N.
Arun, B. K.
CANCER RESEARCH, 2010, 70
[7] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Romond, EH
Perez, EA
Bryant, J
Suman, VJ
Geyer, CE
Davidson, NE
Tan-Chiu, E
Martino, S
Paik, S
Kaufman, PA
Swain, SM
Pisansky, TM
Fehrenbacher, L
Kutteh, LA
Vogel, VG
Visscher, DW
Yothers, G
Jenkins, RB
Brown, AM
Dakhil, SR
Mamounas, EP
Lingle, WL
Klein, PM
Ingle, JN
Wolmark, N
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
[8] Prevalence of germline TP53 mutations in HER2+ breast cancer patients
Michelle G. Rath
Serena Masciari
Rebecca Gelman
Alexander Miron
Penelope Miron
Kathleen Foley
Andrea L. Richardson
Ian E. Krop
Sigitas J. Verselis
Deborah A. Dillon
Judy E. Garber
Breast Cancer Research and Treatment, 2013, 139 : 193 - 198
[9] Prevalence of germline TP53 mutations in HER2+breast cancer patients
Rath, Michelle G.
Masciari, Serena
Gelman, Rebecca
Miron, Alexander
Miron, Penelope
Foley, Kathleen
Richardson, Andrea L.
Krop, Ian E.
Verselis, Sigitas J.
Dillon, Deborah A.
Garber, Judy E.
BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 193 - 198
[10] The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer
Carla Escudeiro
Carla Pinto
Joana Vieira
Ana Peixoto
Pedro Pinto
Manuela Pinheiro
Catarina Santos
Joana Guerra
Susana Lisboa
Rui Santos
João Silva
Conceição Leal
Nuno Coimbra
Paula Lopes
Marco Ferreira
Ana B. Sousa
Manuel R. Teixeira
Familial Cancer, 2021, 20 : 173 - 180

← 1 2 3 4 5 →